Alcon Inc. (ALC)
Alcon: Product Cycle Reset Creates An Attractive Entry Point (Initiating Buy)
Alcon receives a buy rating, driven by the launch of Tryptyr in the mature dry eye disease market. Tryptyr's unique mechanism and rapid tear production differentiate it, but commercial adoption hinges on refill rates, payer coverage, and patient persistence. ALC's robust commercial footprint and strong balance sheet support ongoing R&D, M&A, dividends, and buybacks, mitigating financing risks.
Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?
Alcon's Surgical and Vision Care units returned to 6% growth in Q1 2026, but tariffs, macro pressure and fierce competition still loom.
Here's Why Alcon (ALC) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Alcon Inc. (ALC) Q1 2026 Earnings Call Transcript
Alcon Inc. (ALC) Q1 2026 Earnings Call Transcript
Swiss eye care firm Alcon's quarterly revenue rises, driven by product launches
Swiss-American eye care company Alcon reported a 10% rise in its quarterly revenue, citing recent product launches as main drivers.
ALC vs. PEN: Which Stock Should Value Investors Buy Now?
Investors with an interest in Medical - Instruments stocks have likely encountered both Alcon (ALC) and Penumbra (PEN). But which of these two stocks presents investors with the better value opportunity right now?
Alcon Inc (ALC) Stock Down 3.1% -- Now Undervalued? GF Score: 80/100
On April 21, 2026, Alcon Inc (ALC) shares fell 3.1% today to a current price of $77.82. This decline comes amid a 52-week range of $71.55 to $99.20, reflecting
Are Medical Stocks Lagging Alcon (ALC) This Year?
Here is how Alcon (ALC) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.
STAAR Surgical: Q1 Preliminary Revenues Justify Decision To Reject Alcon Bid
STAAR Surgical Company has seen a dramatic valuation reset, now trading at a $1bn market cap after failed acquisition talks and underwhelming US growth. Q1 2026 net sales are expected to exceed $90m, driven by a strong rebound in China and signaling potential for record annual revenues. Despite operational challenges and competitive pressures, STAA's proprietary Collamer lens and expanded US indications provide incremental growth opportunities.
Alcon Stock Gains Following the Launch of Clareon TruPlus at ASCRS
ALC gains after launching Clareon TruPlus IOL, expanding its portfolio with enhanced depth of focus while maintaining high-quality distance vision.
5 Medical Instruments Stocks to Buy Amid Huge Short-Term Price Upside
ISRG, GMED, EW, ALC and IRMD show strong short-term upside as AI tools, acquisitions and new product pipelines fuel growth.
Is Alcon (ALC) Stock Outpacing Its Medical Peers This Year?
Here is how Alcon (ALC) and Anavex Life Sciences (AVXL) have performed compared to their sector so far this year.
